POLOMAR Health files late 10-Q notice for Q1 2026

POLOMAR HEALTH SERVICES, INC. submitted a Form 12b-25 notifying the SEC of a late Form 10-Q for the quarter ended March 31, 2026 because it could not timely compile required quarterly financial statements.

Rhea-AI Filing Summary

POLOMAR HEALTH SERVICES, INC. submitted a Form 12b-25 notifying the SEC of a late Form 10-Q for the quarter ended March 31, 2026 because it could not timely compile required quarterly financial statements.

The filing discloses revenues of $1,005,519 for the three months ended March 31, 2026, versus $4,542 in the prior-year quarter, operating expenses of $575,850, and a net loss of $25,379. Management attributes revenue growth to a change from a retail to a wholesale business model and cites increased fulfillment of sterile compounded drug prescriptions. The company states it is working to complete and file the Quarterly Report as soon as possible.

Insights

Accounting & Reporting Specialist

Late 10-Q filing due to incomplete quarter-end financial statements.

The company invoked Rule 12b-25, stating it could not, "without unreasonable effort or expense," complete financials for the quarter ended March 31, 2026. The notice is procedural and explains the cause rather than quantifying unresolved audit or review items.

Key dependencies are completion of financial statement compilation and any required accountant statement under Rule 12b-25(c). Subsequent filings should clarify remaining items and finalize numbers; timing is not specified beyond management's intent to file "as soon as possible."

Financial Operations Analyst

Quarter shows meaningful revenue shift tied to business-model change.

Reported revenue for Q1 2026 was $1,005,519, up from $4,542 a year earlier, attributed to a shift to wholesale and increased sterile drug prescription fulfillment. Operating expenses rose to $575,850, led by shipping and payroll costs.

While revenue growth is notable, the filing records a net loss of $25,379. Future filings should confirm revenue recognition policies and margin dynamics once the full 10-Q is filed.

Key Figures

Revenue (Q1 2026): $1,005,519 Revenue (Q1 2025): $4,542 Operating expenses (Q1 2026): $575,850 +4 more

7 metrics

Revenue (Q1 2026) $1,005,519 Three months ended March 31, 2026

Revenue (Q1 2025) $4,542 Three months ended March 31, 2025

Operating expenses (Q1 2026) $575,850 Three months ended March 31, 2026

Net loss (Q1 2026) $25,379 Three months ended March 31, 2026

Shipping expenses (Q1 2026) $276,379 Three months ended March 31, 2026

Payroll (Q1 2026) $188,889 Three months ended March 31, 2026

Legal and accounting fees (Q1 2026) $66,892 Three months ended March 31, 2026

Key Terms

Rule 12b-25, Form 10-Q, sterile compounded drug prescriptions, wholesale business model, +1 more

5 terms

Rule 12b-25 regulatory

"could not be filed without unreasonable effort or expense"

Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

Form 10-Q regulatory

"Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

sterile compounded drug prescriptions medical

"increase in fulfillment of sterile compounded drug prescriptions"

wholesale business model financial

"change from a retail to a wholesale business model"

planned merger with Altanine, Inc. corporate

"legal and accounting fees associated with the registrant’s SEC filings and planned merger with Altanine, Inc."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did POLOMAR HEALTH SERVICES (PMHS) file a Form 12b-25?

The company filed because it could not timely compile all required financial statements for the quarter ended March 31, 2026. It invoked Rule 12b-25 and said it is working to complete the quarterly report as soon as possible.

How much revenue did PMHS report for the quarter ended March 31, 2026?

POLOMAR reported revenues of $1,005,519 for the three months ended March 31, 2026. Management attributes the increase to a shift from retail to a wholesale model and greater fulfillment of sterile compounded prescriptions.

What were PMHS's operating expenses and main cost drivers in Q1 2026?

Operating expenses were approximately $575,850, driven mainly by shipping expenses of $276,379, payroll of $188,889, and legal and accounting fees of $66,892. These items composed the primary expense increase.

Did PMHS record a profit or loss for the quarter ended March 31, 2026?

The registrant recorded a net loss of approximately $25,379 for the three months ended March 31, 2026. This compares with a net loss of approximately $415,408 for the prior-year quarter.

Are any other periodic reports missing from PMHS over the past 12 months?

According to the notification, all other periodic reports required under Section 13 or 15(d) have been filed during the preceding 12 months. The registrant answered "Yes" to that question on the form.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 01:28 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check one):		☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR
		For Period Ended:	March 31, 2026
		☐ Transition Report on Form 10-K
		☐ Transition Report on Form 20-F
		☐ Transition Report on Form 11-K
		☐ Transition Report on Form 10-Q
		☐ Transition Report on Form N-SAR
		For the Transition Period Ended:

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I — REGISTRANT INFORMATION

POLOMAR HEALTH SERVICES, INC.

Full Name of Registrant

Former Name if Applicable

32866 US Hwy. 19 N

Address of Principal Executive Office (Street and Number)

Palm Harbor, FL 34684

City, State and Zip Code

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

☐		(a)	The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
		(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
		(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report portion thereof, could not be filed within the prescribed time period.

The Registrant has been unable, without unreasonable effort or expense, to timely compile all information for the financial statements required to be included in its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 (the “Quarterly Report”). The Company is working diligently to complete the financial statements for the fiscal quarter ended March 31, 2026, and the quarterly report as soon as possible.

SEC 1344 (04-09) Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(Attach extra Sheets if Needed)

PART IV — OTHER INFORMATION

(1)	Name and telephone number of person to contact in regard to this notification
	Terrence M. Tierney		(727)		425-7575
	(Name)		(Area Code)		(Telephone Number)

(2)	Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
	Yes ☒ No ☐
(3)	Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
	Yes ☒ No ☐
	If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
	The registrant had revenues of approximately $1,005,519 for the three months ended March 31, 2026, compared to $4,542 for the three months ended March 31, 2025. The increase in revenues over the previous accounting period was primarily due to the registrant’s change from a retail to a wholesale business model with a significant increase in fulfillment of sterile compounded drug prescriptions.
	Operating expenses, which consisted mainly of general and administrative expenses, increased to approximately $575,850 for the three months ended March 31, 2026, from approximately $398,836 for the three months ended March 31, 2025. Operating expenses for the three months ended March 31, 2026, consisted mainly of shipping expenses of approximately $276,379, payroll of approximately $188,889, and legal and accounting fees associated with the registrant’s SEC filings and planned merger with Altanine, Inc. of approximately $66,892. In comparison, the registrant’s operating expenses for the three months ended March 31, 2025, consisted mainly of legal and accounting fees associated with the registrant’s SEC filings of approximately $63,399, consulting fees of approximately $48,000 and payroll of approximately $67,568.
	The registrant recorded a net loss of approximately $25,379 for the three months ended March 31, 2026, as compared with a net loss of approximately $415,408 for the three months ended March 31, 2025, as a result of the expenses incurred and insufficient revenues generated during the period, as described further above.

POLOMAR HEALTH SERVICES, INC.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date:	May 18, 2026	By:	/s/ Terrence M. Tierney
			Terrence M. Tierney
			President